Posted by
on Jan 19th, 2012 and filed under FDA Rejects Dapagliflozin for Type 2 Diabetes – MedPage Today
Updated News
MedPage Today
By Emily P. Walker, Washington Correspondent, MedPage Today WASHINGTON — The FDA said it would not approve the novel diabetes drug dapagliflozin until drugmakers Bristol-Myers Squibb and AstraZeneca supply more data on the drug's benefits and risks. …
FDA rejects dapagliflozin for diabetes, raising concerns for a class
FDA Asks BMS, AstraZeneca for More Clinical Data for Antidiabetic
US rebuffs AstraZeneca, Bristol on diabetes drug
FDA Rejects Dapagliflozin for Type 2 Diabetes – MedPage Today Updated News FDA Rejects Dapagliflozin for Type 2 DiabetesMedPage TodayBy Emily P. Walker, Washington Correspondent, MedPage Today WASHINGTON — The FDA said it would not approve the novel diabetes drug dapagliflozin until drugmakers Bristol-Myers Squibb and AstraZeneca supply more data on the drug's benefits and [...]
